Transcatheter edge-to-edge repair (TEER) with the MitraClip (Abbott) to treat functional and degenerative mitral regurgitation (MR) fails relatively infrequently when performed at high-volume centers, ...

Chicago, IL—Real-world patients with mitral regurgitation (MR) not meeting the COAPT eligibility criteria who ultimately underwent clip-based transcatheter mitral valve repair fared just as well as ...

In 2013, the FDA approved an implantable device to treat leaky heart valves. Among its inventors was Mehmet Oz, the former television personality and former U.S. Senate candidate widely known as "Dr.

CHICAGO -- Emerging real-world data supported benefits of MitraClip therapy in patients with secondary mitral regurgitation (MR) who didn't fit the COAPT profile, the EXPAND study showed. MR was often ...

Surgical repair decreased MR more than MitraClip ®. In 12-month follow-up, 20% of MitraClip patients required surgery for mitral dysfunction versus 2% in surgical patients. Both groups had ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter mitral valve repair improved outcomes and symptoms in patients with moderate to severe mitral ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...

WASHINGTON, D.C., Oct. 24, 2007 – The vast majority of patients who had a successful result with the percutaneous MitraClip device did not need mitral valve surgery three years after their procedure, ...

A study from Abbott found that employing its cardiac valve repair implant during earlier phases of heart failure—when a patient’s leaky mitral valve is still considered to be functional—could lead to ...

Abbott Laboratories, Inc. ABT recently presented late-breaking data from the Landmark COAPT trial for MitraClip, demonstrating the long-term benefits of the device in patients fighting heart failure.

Americans rely on the Food and Drug Administration to make sure that medical devices are safe. Reporting by KFF Health News has raised questions about how the FDA has dealt with some products, ...